NEW YORK, April 26 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will be presenting at the following upcoming Investor Conferences:
Wednesday, May 2nd, 2007 - 8:45 AM ET: Morgan Stanley Global Healthcare Unplugged Conference The Ritz Carlton Key Biscayne Key Biscayne, Florida Thursday, May 3rd, 2007 - 9:45am ET: Deutsche Bank 32nd Annual Health Care Conference The Mayflower Hotel Washington, DC
Each of Mr. Weiss' presentations will be webcast live and may be accessed from the Investor Information page of the Company's Website at http://investors.keryx.com . An archived version of each presentation webcast will be available following the conclusion of the live presentation.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide oral gelcap), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end- stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in- class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.
KERYX CONTACT: Ron Renaud Chief Financial Officer Keryx Biopharmaceuticals, Inc. Tel: 212.531.5965 E-mail: rrenaud@keryx.com
Keryx Biopharmaceuticals, Inc.CONTACT: Ron Renaud, Chief Financial Officer of Keryx Biopharmaceuticals,Inc., +1-212-531-5965, or rrenaud@keryx.com
Web site: http://investors.keryx.com/
